English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been found to exploit the cell’s ACE2 receptor for viral entry. Renin-angiotensin-aldosterone system (RAAS) antagonism with angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) increases the expression of ACE2 receptors which, coupled with the metabolic changes associated with obesity-related hypertension, can make hypertensive patients with obesity more vulnerable to severe COVID-19. Although current evidence suggests that ACEI/ARB use does not increase risk of severe COVID-19 in the general population, potential interactions with obesity-related hypertension are unknown. Methods: We conducted a retrospective study of COVID-19 patients admitted to the University of Iowa Hospitals and Clinics between March 1st and July 8th, 2020. We included adults who are overweight (BMI ≥ 25 kg/m2) or obese (BMI ≥ 30 kg/m2) with hypertension treated as outpatients with or without ACEIs/ARBs. Patients without exposure to RAAS antagonists served as controls. We assessed mortality and the severity of COVID-19 reflected by admission to ICU and usage of supplemental O2, non-invasive ventilation, mechanical ventilation, extracorporeal membrane oxygenation (ECMO) and vasopressors. Results: Of the 369 inpatients with COVID-19, we identified 138 exhibiting obesity-related hypertension who were then allocated into the control (n=59) and ACEI/ARB (n=79) groups. The BMIs between groups at baseline were not statistically significant (Control: 33.6 ± 0.96 vs. ACEI/ARB: 34.99 ± 0.97; p=.32). Women were less represented in the ACEI/ARB group (Control: 47% vs. ACEI/ARB: 24%). The controls had a substantially higher mortality rate (Control: 32.2% vs. ACEI/ARB: 15.1%). In regard to the severity of COVID-19, the ACEI/ARB cohort showed lower usage of supplemental O2 (Control: 52.5% vs. ACEI/ARB: 49.3%), mechanical ventilation (Control: 37.2% vs. ACEI/ARB: 1.2%), vasopressors (Control: 38.9% vs. ACEI/ARB: 31.6%), and had lower ICU admissions (Control: 57.6% vs. ACEI/ARB: 46.8%). However, the ACEI/ARB group had higher rates of: ECMO (Control: 0% vs. ACEI/ARB: 20.2%) and non-invasive ventilation (Control: 18.6% vs. ACEI/ARB: 20.2%). Of note, the rate of diabetes was higher in the ACEI/ARB cohort (Control: 45.7% vs. ACEI/ARB: 63.2%). Conclusion: Our results suggest that a history of RAAS antagonism is associated with lower mortality and less severity of COVID-19 in patients with obesity-related hypertension requiring hospital admission.

journal of the endocrine society

Patients With Obesity-Related Hypertension Treated With Renin-Angiotensin-Aldosterone System Antagonists Exhibit Lower Mortality And Less Severe COVID-19: A Retrospective Study